Psychopharmacologia

, Volume 5, Issue 5, pp 361–371 | Cite as

Psychopharmacology of imipramine and desipramine: A comparative study of their effects in normal males

  • Alberto Di Mascio
  • George Heninger
  • Gerald L. Klerman
Original Investigations

Summary

The effects of imipramine and desipramine were each examined at three dose levels in normal males. A placebo-controlled, double-blind procedure was employed. Effects were measured in a variety of behavioral and subjective responses. The resulting drug-action profiles reveal that imipramine produced hypnotic-like actions, as evidenced by the observation — and subjective reports — of marked sleepiness and concomitant impairment of intelectual and visuo-motor functioning. Side-effects of a cardiovascular, gastrointestinal disturbing, or anticholinergiclike nature were often experienced.

In contrast, desipramine produced effects in only two of the areas measured — a slight increase in sleepiness and a rise in pulse rate. The increased sleepiness was not accompanied by self-reports of a generalized impairment of performance, nor by actual decrements in performance measures. The side-effects reported were few in number and minimal in degree.

For both drugs the effects were dose related, maximal 2 1/2 hours after ingestion, and had subsided within 7 hours. The relationship of these effects to chemostructural variations, to clinical applications, and to possible modes of action of the two drugs were discussed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ban, T. A., and H. E. Lehmann: Clinical trial with desmethylimipramine, a new antidepressant compound. Canad. med. Ass. J. 86, 1030–1031 (1962).Google Scholar
  2. Brodie, B., P. Dick, P. Kielholz, W. Poldinger, and W. Theobald: Preliminary pharmacological and clinical results with desmethylimipramine, a metabolite of imipramine. Psychopharmacologia (Berl.) 2, 467–474 (1961).Google Scholar
  3. Denber, H. C. B.: Chlorpromazine-diethazine in the treatment of depression. Dis. nerv. Syst. (Monograph Suppl.) 18 (7), 1–4 (1957).Google Scholar
  4. Dimascio, A., L. Havens, and G. Klerman: The psychopharmacology of phenothiazine compounds: A comparative study of the effects of chlorpromazine, promethazine, trifluoperazine, and perphenazine in normal males. J. nerv. ment. Dis. 136 (1), 15–28; 136 (2), 168–186 (1963)Google Scholar
  5. Domenjoz, R., u. W. Theobald: Zur Pharmakologie des Tofranil (N-(3-Dimethylaminopropyl)-iminodibenzylhydrochlorid). Arch. int. Pharmacodyn. 120, 450–489 (1959).Google Scholar
  6. Flach, F. F., and P. F. Regan: Chemotherapy in emotional disorders. New York: McGraw-Hill Book Co. 1960.Google Scholar
  7. Frommel, E., C. Fleury, et J. Schmidt-Genzkey: De l'action psychoanaleptique du Tofranil. Schweiz. med. Wschr. 90, 830 (1960).Google Scholar
  8. Hill, R. T., I. Koosis, M. W. Minor, and E. B. Sigg: The potentiation of methylphenidate by imipramine, amitriptyline and their desmethyl analogues. Pharmacologist 3, 75 (1961).Google Scholar
  9. Hollister, L. E., J. E. Overall, J. Shelton, M. Johnson, G. Katz, and V. Pennington: Controlled study of desipramine in depression. J. New Drugs (in press).Google Scholar
  10. Lehmann, H. E., C. H. Cahn, and R. L. DeVerteuil: The treatment of depressive conditions with imipramine. Canad. psychiat. Ass. J. 3 (4), 155–164 (1958).Google Scholar
  11. Mann, A.: Desmethylimipramine in the treatment of depression: Pilot study in a general hospital and outpatient setting. Canad. med. Ass. J. 86, 495–598 (1962).Google Scholar
  12. Meduna, L. J., L. G. Abood, and J. H. Brel: (N(-Methylaminopropyl) Iminodibenzyl: A new antidepressant. J. Neuropsychiat. 2, 232–237 (1961).Google Scholar
  13. Oltman, J. E., and S. Friedman: Preliminary investigation of desmethylimipramine. Amer. J. Psychiat. 119 (4), 370–371 (1962).Google Scholar
  14. Pletscher, A., u. K. F. Gey: Pharmakologische Beeinflussung des 5-Hydroxytryptamine-Stoffwechsels im Gehirn und Monoaminoxydasehemmung in vitro. Helv. physiol. pharmacol. Acta 17, C 35 (1959).Google Scholar
  15. Poldinger, W.: Comparison between imipramine and desipramine in normal subjects and their actions in depressive patients. Psychopharmacologia (Berl.) 4, 302–307 (1963).Google Scholar
  16. Pollack, B.: Clinical findings in the use of Tofranil in depressives and other psychiatric states. Amer. J. Psychiat. 116, 312 (1959).Google Scholar
  17. Pulver, R., B. Exer u. B. Herrmann: Einige Wirkungen des N-(Dimethylaminopropyl)-iminodibenzyl-HCL und seiner Metabolite auf den Stoffwechsel von Neurohormonen. Arzneimittel-Forsch. 10, 530–533 (1960).Google Scholar
  18. Schaeppi, U.: Die Beeinflussung der Reizübertragung im peripheren Sympathicus durch Tofranil. Helv. physiol. pharmacol. Acta 18, 545–562 (1960).Google Scholar
  19. Sigg, E. B.: Pharmacological studies with Tofranil. Canad. Psychiat. Ass. J. 4, 75–83 (1959), Special Suppl.Google Scholar
  20. Stein, L., and J. Seifter: Possible model of antidepressive action of imipramine. Science 134 (3474), 286–287 (1961).Google Scholar
  21. Sulser, F., J. Watts, and B. B. Brodie: On the mechanism of antidepressant action of imipramine-like drugs. Ann. N.Y. Acad. Sci. 96, 279–288 (1962).Google Scholar

Copyright information

© Springer-Verlag 1964

Authors and Affiliations

  • Alberto Di Mascio
    • 1
    • 2
  • George Heninger
    • 1
    • 2
  • Gerald L. Klerman
    • 1
    • 2
  1. 1.Psychopharmacology Research LaboratoryMassachusetts Mental Health CenterBoston 15
  2. 2.Department of PsychiatryHarvard Medical SchoolBoston 15

Personalised recommendations